Cargando…

Development, Validation of LC-MS/MS Method and Determination of Pharmacokinetic Parameters of the Stroke Neuroprotectant Neurounina-1 in Beagle Dog Plasma After Intravenous Administration

Neurounina-1 [chemical name: 7-nitro-5-phenyl-1-(pyrrolidin-1-ylmethyl)-1H-benzo[e][1,4]diazepin-2(3H)-one] is a new compound provided with relevant neuroprotective effect during stroke and in neonatal hypoxia by increasing the Na(+)/Ca(2+) exchanger (NCX) isoforms NCX1 and NCX2 activity. This study...

Descripción completa

Detalles Bibliográficos
Autores principales: Severino, Beatrice, Corvino, Angela, Fiorino, Ferdinando, Frecentese, Francesco, Perissutti, Elisa, Caliendo, Giuseppe, Santagada, Vincenzo, Magli, Elisa, Molinaro, Pasquale, Pignataro, Giuseppe, Annunziato, Lucio, Antunes, Natalícia J., Rojas-Moscoso, Julio, de Freitas, Noedi L., Mendes, Gustavo D., De Nucci, Gilberto
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Frontiers Media S.A. 2019
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6497007/
https://www.ncbi.nlm.nih.gov/pubmed/31073288
http://dx.doi.org/10.3389/fphar.2019.00432
_version_ 1783415403502895104
author Severino, Beatrice
Corvino, Angela
Fiorino, Ferdinando
Frecentese, Francesco
Perissutti, Elisa
Caliendo, Giuseppe
Santagada, Vincenzo
Magli, Elisa
Molinaro, Pasquale
Pignataro, Giuseppe
Annunziato, Lucio
Antunes, Natalícia J.
Rojas-Moscoso, Julio
de Freitas, Noedi L.
Mendes, Gustavo D.
De Nucci, Gilberto
author_facet Severino, Beatrice
Corvino, Angela
Fiorino, Ferdinando
Frecentese, Francesco
Perissutti, Elisa
Caliendo, Giuseppe
Santagada, Vincenzo
Magli, Elisa
Molinaro, Pasquale
Pignataro, Giuseppe
Annunziato, Lucio
Antunes, Natalícia J.
Rojas-Moscoso, Julio
de Freitas, Noedi L.
Mendes, Gustavo D.
De Nucci, Gilberto
author_sort Severino, Beatrice
collection PubMed
description Neurounina-1 [chemical name: 7-nitro-5-phenyl-1-(pyrrolidin-1-ylmethyl)-1H-benzo[e][1,4]diazepin-2(3H)-one] is a new compound provided with relevant neuroprotective effect during stroke and in neonatal hypoxia by increasing the Na(+)/Ca(2+) exchanger (NCX) isoforms NCX1 and NCX2 activity. This study shows for the first time, the development and validation of a sensitive and selective method for analysis of neurounina-1 in beagle dog plasma by liquid chromatography coupled to tandem mass spectrometry (LC-MS/MS). The sample preparation consisted of extraction of the analyte and the internal standard (IS) (ropivacaine) from plasma (50 μL) by liquid-liquid extraction using acetonitrile (100 μL). The selected reaction monitoring mode of the positive ion was performed and the precursor to the product ion transitions of m/z 365 > 83 and m/z 275 > 126 were used to measure the derivative of neurounina-1 and ropivacaine. The chromatographic separation was achieved using a Phenomenex C18 Luna (150 mm × 4.6 mm × 5 μm) analytical column with an isocratic mobile phase composed of methanol/acetonitrile/water (50/40/10, v/v/v) + 0.1% formic acid + 1 M ammonium formate. The method was linear over a concentration range of 1–500 ng/mL. The method was applied to evaluate the pharmacokinetics of neurounina-1 after a single intravenous administration of three different doses (0.1 mg/kg, 0.3 mg/kg, and 1 mg/kg) to beagle dogs (n = 5). The mean AUC(0-tlast) values were 26.10, 115.81, and 257.28 ng(∗)h/mL following intravenous administration of 0.1, 0.3, and 1 mg/kg, respectively. Linear pharmacokinetics was observed up to 1.0 mg/kg. The neurounina-1 was rapidly eliminated, with mean CL values of 46.24, 47.57, and 69.15 L/h, Vd of 130.31, 154.15, and 210.79 L and t(1/2) of 2.14, 2.54, and 2.04 h after intravenous administration of 0.1, 0.3, and 1 mg/kg, respectively. This new analytical method allows the rapid determination of the neurounina-1, a new developed compound, able to exert a remarkable neuroprotective effect in the low nanomolar range.
format Online
Article
Text
id pubmed-6497007
institution National Center for Biotechnology Information
language English
publishDate 2019
publisher Frontiers Media S.A.
record_format MEDLINE/PubMed
spelling pubmed-64970072019-05-09 Development, Validation of LC-MS/MS Method and Determination of Pharmacokinetic Parameters of the Stroke Neuroprotectant Neurounina-1 in Beagle Dog Plasma After Intravenous Administration Severino, Beatrice Corvino, Angela Fiorino, Ferdinando Frecentese, Francesco Perissutti, Elisa Caliendo, Giuseppe Santagada, Vincenzo Magli, Elisa Molinaro, Pasquale Pignataro, Giuseppe Annunziato, Lucio Antunes, Natalícia J. Rojas-Moscoso, Julio de Freitas, Noedi L. Mendes, Gustavo D. De Nucci, Gilberto Front Pharmacol Pharmacology Neurounina-1 [chemical name: 7-nitro-5-phenyl-1-(pyrrolidin-1-ylmethyl)-1H-benzo[e][1,4]diazepin-2(3H)-one] is a new compound provided with relevant neuroprotective effect during stroke and in neonatal hypoxia by increasing the Na(+)/Ca(2+) exchanger (NCX) isoforms NCX1 and NCX2 activity. This study shows for the first time, the development and validation of a sensitive and selective method for analysis of neurounina-1 in beagle dog plasma by liquid chromatography coupled to tandem mass spectrometry (LC-MS/MS). The sample preparation consisted of extraction of the analyte and the internal standard (IS) (ropivacaine) from plasma (50 μL) by liquid-liquid extraction using acetonitrile (100 μL). The selected reaction monitoring mode of the positive ion was performed and the precursor to the product ion transitions of m/z 365 > 83 and m/z 275 > 126 were used to measure the derivative of neurounina-1 and ropivacaine. The chromatographic separation was achieved using a Phenomenex C18 Luna (150 mm × 4.6 mm × 5 μm) analytical column with an isocratic mobile phase composed of methanol/acetonitrile/water (50/40/10, v/v/v) + 0.1% formic acid + 1 M ammonium formate. The method was linear over a concentration range of 1–500 ng/mL. The method was applied to evaluate the pharmacokinetics of neurounina-1 after a single intravenous administration of three different doses (0.1 mg/kg, 0.3 mg/kg, and 1 mg/kg) to beagle dogs (n = 5). The mean AUC(0-tlast) values were 26.10, 115.81, and 257.28 ng(∗)h/mL following intravenous administration of 0.1, 0.3, and 1 mg/kg, respectively. Linear pharmacokinetics was observed up to 1.0 mg/kg. The neurounina-1 was rapidly eliminated, with mean CL values of 46.24, 47.57, and 69.15 L/h, Vd of 130.31, 154.15, and 210.79 L and t(1/2) of 2.14, 2.54, and 2.04 h after intravenous administration of 0.1, 0.3, and 1 mg/kg, respectively. This new analytical method allows the rapid determination of the neurounina-1, a new developed compound, able to exert a remarkable neuroprotective effect in the low nanomolar range. Frontiers Media S.A. 2019-04-25 /pmc/articles/PMC6497007/ /pubmed/31073288 http://dx.doi.org/10.3389/fphar.2019.00432 Text en Copyright © 2019 Severino, Corvino, Fiorino, Frecentese, Perissutti, Caliendo, Santagada, Magli, Molinaro, Pignataro, Annunziato, Antunes, Rojas-Moscoso, de Freitas, Mendes and De Nucci. http://creativecommons.org/licenses/by/4.0/ This is an open-access article distributed under the terms of the Creative Commons Attribution License (CC BY). The use, distribution or reproduction in other forums is permitted, provided the original author(s) and the copyright owner(s) are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms.
spellingShingle Pharmacology
Severino, Beatrice
Corvino, Angela
Fiorino, Ferdinando
Frecentese, Francesco
Perissutti, Elisa
Caliendo, Giuseppe
Santagada, Vincenzo
Magli, Elisa
Molinaro, Pasquale
Pignataro, Giuseppe
Annunziato, Lucio
Antunes, Natalícia J.
Rojas-Moscoso, Julio
de Freitas, Noedi L.
Mendes, Gustavo D.
De Nucci, Gilberto
Development, Validation of LC-MS/MS Method and Determination of Pharmacokinetic Parameters of the Stroke Neuroprotectant Neurounina-1 in Beagle Dog Plasma After Intravenous Administration
title Development, Validation of LC-MS/MS Method and Determination of Pharmacokinetic Parameters of the Stroke Neuroprotectant Neurounina-1 in Beagle Dog Plasma After Intravenous Administration
title_full Development, Validation of LC-MS/MS Method and Determination of Pharmacokinetic Parameters of the Stroke Neuroprotectant Neurounina-1 in Beagle Dog Plasma After Intravenous Administration
title_fullStr Development, Validation of LC-MS/MS Method and Determination of Pharmacokinetic Parameters of the Stroke Neuroprotectant Neurounina-1 in Beagle Dog Plasma After Intravenous Administration
title_full_unstemmed Development, Validation of LC-MS/MS Method and Determination of Pharmacokinetic Parameters of the Stroke Neuroprotectant Neurounina-1 in Beagle Dog Plasma After Intravenous Administration
title_short Development, Validation of LC-MS/MS Method and Determination of Pharmacokinetic Parameters of the Stroke Neuroprotectant Neurounina-1 in Beagle Dog Plasma After Intravenous Administration
title_sort development, validation of lc-ms/ms method and determination of pharmacokinetic parameters of the stroke neuroprotectant neurounina-1 in beagle dog plasma after intravenous administration
topic Pharmacology
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6497007/
https://www.ncbi.nlm.nih.gov/pubmed/31073288
http://dx.doi.org/10.3389/fphar.2019.00432
work_keys_str_mv AT severinobeatrice developmentvalidationoflcmsmsmethodanddeterminationofpharmacokineticparametersofthestrokeneuroprotectantneurounina1inbeagledogplasmaafterintravenousadministration
AT corvinoangela developmentvalidationoflcmsmsmethodanddeterminationofpharmacokineticparametersofthestrokeneuroprotectantneurounina1inbeagledogplasmaafterintravenousadministration
AT fiorinoferdinando developmentvalidationoflcmsmsmethodanddeterminationofpharmacokineticparametersofthestrokeneuroprotectantneurounina1inbeagledogplasmaafterintravenousadministration
AT frecentesefrancesco developmentvalidationoflcmsmsmethodanddeterminationofpharmacokineticparametersofthestrokeneuroprotectantneurounina1inbeagledogplasmaafterintravenousadministration
AT perissuttielisa developmentvalidationoflcmsmsmethodanddeterminationofpharmacokineticparametersofthestrokeneuroprotectantneurounina1inbeagledogplasmaafterintravenousadministration
AT caliendogiuseppe developmentvalidationoflcmsmsmethodanddeterminationofpharmacokineticparametersofthestrokeneuroprotectantneurounina1inbeagledogplasmaafterintravenousadministration
AT santagadavincenzo developmentvalidationoflcmsmsmethodanddeterminationofpharmacokineticparametersofthestrokeneuroprotectantneurounina1inbeagledogplasmaafterintravenousadministration
AT maglielisa developmentvalidationoflcmsmsmethodanddeterminationofpharmacokineticparametersofthestrokeneuroprotectantneurounina1inbeagledogplasmaafterintravenousadministration
AT molinaropasquale developmentvalidationoflcmsmsmethodanddeterminationofpharmacokineticparametersofthestrokeneuroprotectantneurounina1inbeagledogplasmaafterintravenousadministration
AT pignatarogiuseppe developmentvalidationoflcmsmsmethodanddeterminationofpharmacokineticparametersofthestrokeneuroprotectantneurounina1inbeagledogplasmaafterintravenousadministration
AT annunziatolucio developmentvalidationoflcmsmsmethodanddeterminationofpharmacokineticparametersofthestrokeneuroprotectantneurounina1inbeagledogplasmaafterintravenousadministration
AT antunesnataliciaj developmentvalidationoflcmsmsmethodanddeterminationofpharmacokineticparametersofthestrokeneuroprotectantneurounina1inbeagledogplasmaafterintravenousadministration
AT rojasmoscosojulio developmentvalidationoflcmsmsmethodanddeterminationofpharmacokineticparametersofthestrokeneuroprotectantneurounina1inbeagledogplasmaafterintravenousadministration
AT defreitasnoedil developmentvalidationoflcmsmsmethodanddeterminationofpharmacokineticparametersofthestrokeneuroprotectantneurounina1inbeagledogplasmaafterintravenousadministration
AT mendesgustavod developmentvalidationoflcmsmsmethodanddeterminationofpharmacokineticparametersofthestrokeneuroprotectantneurounina1inbeagledogplasmaafterintravenousadministration
AT denuccigilberto developmentvalidationoflcmsmsmethodanddeterminationofpharmacokineticparametersofthestrokeneuroprotectantneurounina1inbeagledogplasmaafterintravenousadministration